Company profile: Spotlight Therapeutics
1.1 - Company Overview
Company description
- Provider of targeted biologic gene editing solutions, including Targeted Active Gene Editors (cell-targeted CRISPR-Cas ribonucleoproteins) for non-viral in vivo delivery in immuno-oncology and genetic diseases; localized eRNP editing for retinal cells via subretinal delivery; eRNP applications in the CNS; and a high-throughput screen to identify Cas fusion proteins for selective internalization and localization in primary cells.
Products and services
- Targeted Active Gene Editors (TAGE): Custom-engineered CRISPR-Cas ribonucleoproteins enable non-viral, cell-targeted in vivo editing in specific cell populations for immuno-oncology and genetic diseases
- High-throughput screen for CRISPR-Cas delivery: Assay-based method identifies Cas fusion proteins with selective internalization and subcellular localization in primary cells, improving gene editing delivery efficiency
- ERNP-based gene editing for ocular diseases: Site-specific subretinal delivery of eRNPs enables localized, in vivo retinal cell editing for inherited retinal disorders and broader ocular indications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Spotlight Therapeutics
CASI Pharmaceuticals
HQ: United States
Website
- Description: Provider of business development aimed at building a pipeline through mutually beneficial transactions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CASI Pharmaceuticals company profile →
ImmunoGen
HQ: United States
Website
- Description: Provider of antibody-based anticancer therapeutics using TAP, ELAHERE for platinum-resistant ovarian cancer; investigational IMGN632 for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm; mirvetuximab soravtansine (monotherapy, with bevacizumab or carboplatin) for platinum-sensitive ovarian cancers; and IMGN151 for recurrent endometrial and high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmunoGen company profile →
Five Prime Therapeutics
HQ: United States
Website
- Description: Provider of cancer treatment biotechnology, discovering and developing novel therapeutic proteins and antibodies by systematically screening all relevant human proteins to find the best for each clinical indication, enabled by its ProScreen Engine for rapid production and screening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Five Prime Therapeutics company profile →
Med BioGene
HQ: Canada
Website
- Description: Provider of life science-focused genomic-based clinical lab development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Med BioGene company profile →
Amphista Therapeutics
HQ: United Kingdom
Website
- Description: Provider of next-generation targeted protein degradation therapies and the Eclipsys drug development platform, harnessing the body's natural processes to selectively remove disease-causing proteins. Solutions address a wide range of diseases, including oncology and CNS disorders, and are designed to overcome limitations of first-generation TPD with broad applicability and improved drug properties.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amphista Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Spotlight Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Spotlight Therapeutics
2.2 - Growth funds investing in similar companies to Spotlight Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Spotlight Therapeutics
4.2 - Public trading comparable groups for Spotlight Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →